Chairman of Molecular Assemblies, a Company commercializing enzymatic writing of DNA.  I have led global companies most of my career, raised nearly $600 million, taken companies public in the US and Europe, built teams, launched products and completed multi million strategic partnerships in life science companies.  Molecular has achieved breakthrough technology to write long, pure strands of DNA, including complex strands not available by other methods.  The technology produces single strand oligos aimed at the CRISPR and protein engineering markets and is also developing for gene synthesis.  This is the age of biology and important to that exciting stage is the ability to engineer biology.  We are playing a key role in making that possible and expanding the applications,